 Age-related macular degeneration, AMD, is a common eye condition which causes progressive vision loss due to the formation of abnormal blood vessels underneath the retina. Current treatments involve the use of anti-angiogenic and anti-veg drugs, but these are often not effective enough or can cause side effects. To address this issue, researchers have developed a novel nanodispersion formulation consisting of two anti-angiogenic and one anti-veg drug. This formulation was designed to deliver the drugs directly to the back of the eye where they are needed most, while minimizing systemic exposure and reducing side effects. The nanodispersion was tested in vitro and in vivo, showing promising results. It has the potential to become a highly effective treatment for AMD. This article was authored by Chandrasekhar Pornusamy, Abhimanyu Sugumaran, Venkateshwaran Krishnaswamy, and others.